Research programme: small molecule therapeutics - PMV Pharmaceuticals
Latest Information Update: 10 Dec 2020
At a glance
- Originator PMV Pharmaceuticals
- Class Antineoplastics; Small molecules; Tumour-agnostic therapies
- Mechanism of Action Tumour suppressor protein p53 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 13 Nov 2020 Early research in Solid tumours in USA (unspecified route) (PMV Pharmaceuticals pipeline November 2020)